BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33460466)

  • 1. Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UK.
    Sharpley FA; Manwani R; Petrie A; Mahmood S; Sachchithanantham S; Lachmann HJ; Martinez De Azcona Naharro A; Gillmore JD; Whelan CJ; Fontana M; Cohen O; Hawkins PN; Wechalekar AD
    Eur J Haematol; 2021 Apr; 106(4):537-545. PubMed ID: 33460466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
    Jain T; Kosiorek HE; Kung ST; Shah VS; Dueck AC; Gonzalez-Calle V; Luft S; Reeder CB; Adams R; Noel P; Larsen JT; Mikhael J; Bergsagel L; Stewart AK; Fonseca R
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):486-492.e1. PubMed ID: 29753692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom.
    Sharpley FA; Petrie A; Mahmood S; Sachchithanantham S; Lachmann HJ; Gillmore JD; Whelan CJ; Fontana M; Martinez-Naharro A; Quarta C; Hawkins PN; Wechalekar AD
    Br J Haematol; 2019 Dec; 187(5):642-652. PubMed ID: 31410841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of autologous stem cell transplant for cardiac AL-amyloidosis and cardiac light chain deposition disease.
    Abdallah AA; Alapat D; Kaur V; Atrash S
    J Oncol Pharm Pract; 2020 Jul; 26(5):1128-1133. PubMed ID: 31795821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferred autologous stem cell transplantation in systemic AL amyloidosis.
    Manwani R; Hegenbart U; Mahmood S; Sachchithanantham S; Kyriakou C; Yong K; Popat R; Rabin N; Whelan C; Dittrich T; Kimmich C; Hawkins P; Schönland S; Wechalekar A
    Blood Cancer J; 2018 Nov; 8(11):101. PubMed ID: 30397193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Autologous Stem Cell Transplantation in Amyloidosis.
    Vaxman I; Dispenzieri A
    Oncology (Williston Park); 2021 Aug; 35(8):471-478. PubMed ID: 34398591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vincristine, Doxorubicin, and Dexamethasone Induction before Autologous Stem Cell Transplantation in Patients with AL Amyloidosis: A Retrospective Comparison with Frontline Stem Cell Transplantation.
    Iijima T; Sawa N; Nakayama Y; Oba Y; Ikuma D; Mizuno H; Yamanouchi M; Suwabe T; Wake A; Kono K; Hoshino J; Ubara Y; Ohashi K
    Intern Med; 2022 Oct; 61(19):2853-2860. PubMed ID: 35228429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
    Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
    Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
    Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy - A Single-Center Cohort Study of 227 Patients.
    Feng J; Zhang C; Shen K; Sun J; Fang Q; Zhang L; Cao X; Zhou D; Li J; Tian Z
    Circ J; 2019 Mar; 83(4):775-782. PubMed ID: 30773521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
    Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients.
    Huang X; Ren G; Chen W; Guo J; Zhao L; Zeng C; Ge Y; Liu Z
    Amyloid; 2021 Jun; 28(2):75-83. PubMed ID: 33084412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
    Gimsing P; Hjertner Ø; Abildgaard N; Andersen NF; Dahl TG; Gregersen H; Klausen TW; Mellqvist UH; Linder O; Lindås R; Tøffner Clausen N; Lenhoff S
    Bone Marrow Transplant; 2015 Oct; 50(10):1306-11. PubMed ID: 26121108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib-Based Chemotherapy with Autologous Stem Cell Transplantation for Monoclonal Gammopathy of Renal Significance: A Case Report and Literature Review.
    Huang J; Sun C; Su H; Zhang C; Xiong J
    Kidney Blood Press Res; 2019; 44(4):858-869. PubMed ID: 31352451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial.
    Minnema MC; Nasserinejad K; Hazenberg B; Hegenbart U; Vlummens P; Ypma PF; Kröger N; Wu KL; Kersten MJ; Schaafsma MR; Croockewit S; de Waal E; Zweegman S; Tick L; Broijl A; Koene H; Bos G; Sonneveld P; Schönland S
    Haematologica; 2019 Nov; 104(11):2274-2282. PubMed ID: 30923094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors, treatments and outcomes of patients with light chain amyloidosis who relapse after autologous stem cell transplantation.
    Zhang Y; Guo J; Chen W; Zhao L; Huang X
    Bone Marrow Transplant; 2024 Mar; 59(3):350-358. PubMed ID: 38148411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009.
    Rosengren S; Mellqvist UH; Nahi H; Forsberg K; Lenhoff S; Strömberg O; Ahlberg L; Linder O; Carlson K
    Bone Marrow Transplant; 2016 Dec; 51(12):1569-1572. PubMed ID: 27694943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.